NCT03964805

Brief Summary

In mammals, uterine environment is at low oxygen concentration (2-8% O2). Thus, human embryo culture under low O2 tension (5%) is now recommended by European Society of Human Reproduction and Embryology (ESHRE) revised guidelines for good practices in in vitro fertilization (IVF) labs. Indeed, hypoxia seems to improve embryo quality at cleavage and blastocyst stages, presumably by reducing damages of oxidative stress (OS). Nevertheless, recent meta-analyses concluded only with a low evidence to a superiority of hypoxia on IVF/ICSI outcomes. Furthermore, a study on mouse embryos suggested a negative impact of OS only at cleavage stage. The aim of the present prospective randomized study was to investigate this hypothesis for the first time in human embryos.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
773

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2016

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 6, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 14, 2019

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 28, 2019

Completed
Last Updated

May 28, 2019

Status Verified

April 1, 2019

Enrollment Period

2 years

First QC Date

May 14, 2019

Last Update Submit

May 24, 2019

Conditions

Keywords

Embryo cultureoxygen tension,embryo quality,extended culture

Outcome Measures

Primary Outcomes (4)

  • Embryo quality at Day 2 between groups A and B.

    Embryo morphology is qualified as the number of blastomeres, degree of cytoplasmic fragmentation, regularity of the cells and presence/absence of multinucleated blastomeres. Day 2 top-quality embryos are defined as 4 regular blastomeres, \<20% cytoplasmic fragmentation, no multinucleations.mbryos are defined as 4/8 regular blastomeres, \<20% cytoplasmic fragmentation, no multinucleations.

    Day 2

  • Embryo quality at Day 3 between groups A and B.

    Embryo morphology is qualified as the number of blastomeres, degree of cytoplasmic fragmentation, regularity of the cells and presence/absence of multinucleated blastomeres. Day 3 top-quality embryos are defined as 8 regular blastomeres, \<20% cytoplasmic fragmentation, no multinucleations.

    Day 3

  • Embryo quality at blastocyst stage (Day 5) between groups A, B and C.

    Blastocyst morphology is assessed according to Gardner and Schoolcraft's classification: degree of blastocele expansion (graded from B1 to B6), inner cell mass and trophectoderm morphology (both graded A, B or C). Day 5 top quality blastocyst are defined as ≥B4AA/AB/BA.

    Day 5

  • Embryo quality at blastocyst stage (Day 6) between groups A, B and C.

    Blastocyst morphology is assessed according to Gardner and Schoolcraft's classification: degree of blastocele expansion (graded from B1 to B6), inner cell mass and trophectoderm morphology (both graded A, B or C). Day 5 top quality blastocyst are defined as ≥B4AA/AB/BA.

    Day 6

Secondary Outcomes (6)

  • Fertilization rate

    Days 1

  • Early cleavage rate

    25 hours after insemination

  • Useable embryo rate

    Days 2/3; 5/6

  • Implantation rate

    4-5 weeks after transfer

  • Clinical pregnancy rate

    4-5 weeks after transfer

  • +1 more secondary outcomes

Study Arms (3)

group A

ACTIVE COMPARATOR

Embryo culture at 20% O2

Other: 20% oxygen

group B

ACTIVE COMPARATOR

Embryo culture at 5% O2

Other: 5% oxygen

group C

ACTIVE COMPARATOR

Embryo culture at 5% O2 and at 20% O2

Other: 20 % and 5 % oxygen

Interventions

culture excusively at 20% O2 (Day 0 to Day 6)

Also known as: culture at 20% O2
group A

culture excusively at 5% O2 (Day 0 to Day 6)

Also known as: culture at 5% O2
group B

culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)

Also known as: culture at 20 % and at 5%O2
group C

Eligibility Criteria

Age18 Years - 39 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 18 - 39 years
  • IVF / ICSI Attempt with Ejaculated Sperm Sperm (Fresh or Frozen)
  • At least 8 oocytes retrieved in total
  • Good understanding of the protocol by the patient
  • Informed and consentment signed of the couple

You may not qualify if:

  • \- Hydrosalpinx

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (10)

  • Ciray HN, Aksoy T, Yaramanci K, Karayaka I, Bahceci M. In vitro culture under physiologic oxygen concentration improves blastocyst yield and quality: a prospective randomized survey on sibling oocytes. Fertil Steril. 2009 Apr;91(4 Suppl):1459-61. doi: 10.1016/j.fertnstert.2008.07.1707. Epub 2008 Aug 22.

    PMID: 18722608BACKGROUND
  • Fischer B, Bavister BD. Oxygen tension in the oviduct and uterus of rhesus monkeys, hamsters and rabbits. J Reprod Fertil. 1993 Nov;99(2):673-9. doi: 10.1530/jrf.0.0990673.

    PMID: 8107053BACKGROUND
  • Guo N, Li Y, Ai J, Gu L, Chen W, Liu Q. Two different concentrations of oxygen for culturing precompaction stage embryos on human embryo development competence: a prospective randomized sibling-oocyte study. Int J Clin Exp Pathol. 2014 Aug 15;7(9):6191-8. eCollection 2014.

    PMID: 25337269BACKGROUND
  • Kasterstein E, Strassburger D, Komarovsky D, Bern O, Komsky A, Raziel A, Friedler S, Ron-El R. The effect of two distinct levels of oxygen concentration on embryo development in a sibling oocyte study. J Assist Reprod Genet. 2013 Aug;30(8):1073-9. doi: 10.1007/s10815-013-0032-z. Epub 2013 Jul 9.

    PMID: 23835722BACKGROUND
  • Kea B, Gebhardt J, Watt J, Westphal LM, Lathi RB, Milki AA, Behr B. Effect of reduced oxygen concentrations on the outcome of in vitro fertilization. Fertil Steril. 2007 Jan;87(1):213-6. doi: 10.1016/j.fertnstert.2006.05.066. Epub 2006 Nov 1.

    PMID: 17081523BACKGROUND
  • Kirkegaard K, Hindkjaer JJ, Ingerslev HJ. Effect of oxygen concentration on human embryo development evaluated by time-lapse monitoring. Fertil Steril. 2013 Mar 1;99(3):738-744.e4. doi: 10.1016/j.fertnstert.2012.11.028. Epub 2012 Dec 11.

    PMID: 23245683BACKGROUND
  • Kovacic B, Vlaisavljevic V. Influence of atmospheric versus reduced oxygen concentration on development of human blastocysts in vitro: a prospective study on sibling oocytes. Reprod Biomed Online. 2008 Aug;17(2):229-36. doi: 10.1016/s1472-6483(10)60199-x.

    PMID: 18681997BACKGROUND
  • Waldenstrom U, Engstrom AB, Hellberg D, Nilsson S. Low-oxygen compared with high-oxygen atmosphere in blastocyst culture, a prospective randomized study. Fertil Steril. 2009 Jun;91(6):2461-5. doi: 10.1016/j.fertnstert.2008.03.051. Epub 2008 Jun 12.

    PMID: 18554591BACKGROUND
  • Wale PL, Gardner DK. Time-lapse analysis of mouse embryo development in oxygen gradients. Reprod Biomed Online. 2010 Sep;21(3):402-10. doi: 10.1016/j.rbmo.2010.04.028. Epub 2010 Aug 5.

    PMID: 20691637BACKGROUND
  • Wale PL, Gardner DK. The effects of chemical and physical factors on mammalian embryo culture and their importance for the practice of assisted human reproduction. Hum Reprod Update. 2016 Jan-Feb;22(1):2-22. doi: 10.1093/humupd/dmv034. Epub 2015 Jul 22.

    PMID: 26207016BACKGROUND

MeSH Terms

Conditions

InfertilityHypoxia

Interventions

Oxygen

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ChalcogensElementsInorganic ChemicalsGases

Study Officials

  • Christophe Sifer

    AP-HP_Hôpital Jean Verdier

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2019

First Posted

May 28, 2019

Study Start

September 1, 2016

Primary Completion

September 6, 2018

Study Completion

December 1, 2018

Last Updated

May 28, 2019

Record last verified: 2019-04